View
239
Download
4
Category
Preview:
Citation preview
PRE-FEASIBILITY REPORT
FOR TERMS OF REFERENCES
October, 2016
SRI KRISHNA PHARMACEUTICALS LIMITED PLOT NO. B-14/1,
MIDC CHINCHOLI,
TALUKA- MOHOL,
SOLAPUR DISTRICT
MAHARASTRA
Studies & Documentation By M/S Pridhvi Enviro Tech pvt. Ltd
Submitted by (MoE&F O.M – S.NO: 122, rev 46,
dated 5.10.2016) Sri Krishna pharmaceuticals Ltd, 184/C, Lawn House Plot No. B-14/1 Vengal Rao Nagar
MIDC, Chincholi Hyderabad-500038
Taluka Mohol Ph: 040-40179770
Solapur (D) Fax: 040-66730926
Maharastra E-Mail: pvr@pridhvienviro.com
SUBMITTED TO MINISTRY OF ENVIRONMENT & FORESTS, GOI
PARYAVARAN BHAWAN, CGO COMPLEX,
LODHI ROAD, NEW DELHI-110003
CONTENTS
S.No. Description Page No.
1 Introduction 1
2 Introduction of the project 2
Introduction of the company and the
proponent
3
3 Project Description 4
3.1 Production Capacity 4
3.2 Manufacturing Process 5
3.3 Raw materials 5
3.4 Water Requirement 5
3.5 Waste generation and control systems 6
3.5.1 Liquid effluents 6
3.5.2 Solid waste management 9
4 Site Analysis 10
4.1 Plant location 10
5 Planning in Brief 16
6 Resource requirement 16
6.1 Power requirement and Supply/ Source 16
6.2 Production facilities , Utilities and
effluent handling facilities
16
6.3 Land requirement 17
7 Air pollution 18
8 Bulk chemical storage 18
9 Base line data studies 19
10 Project financial 19
LIST OF TABLES
LIST OF FIGURES
LIST OF ANNEXURES
Table No. Description Page No.
1.0 Salient Features of the Project 2
2.0 List of Proposed Products 4
3.0 Water Balance Proposed 5
4.0 Solid Waste and Disposal 9
5.0 Utilities /ETP-Proposed 16
6.0 Land Statement 17
7.0 Emission Source Proposed 18
8.0 Storage facilities of bulk chemicals 18
Fig No Description Page No.
1.1 Schematic treatment scheme of high
TDS effluents
7
1.2 Low TDS Effluent Treatment System 8
1.3 Topo Map of the Study Area 12
1.4 Base Map of the Study Area 13
1.5 Photographs of current condition of the
site
14
1.6 Site layout plan 15
Annexure Description
I Typical Technical details of proposed products
II List of Raw materials
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, B-14/1
1
1. Introduction
Sri Krishna Pharmaceuticals Ltd., engaged in manufacturing of Active
Pharmaceutical Ingredients, and Intermediates was established in the
year 1975. Research and Development forms the backbone of the
organization with state of the art instrumentation facilities. They have
Five manufacturing sites in India four in Telangana manufacturing bulk
drugs & formulations and one in Maharastra manufacturing Drug
intermediates.
Sri Krishna Pharmaceuticals limited proposed to establish a new unit at
Plot. No. B-14/1, MIDC, Chincholi, Taluka- Mohol, Solapur District,
Maharastra state.
The unit obtained TOR for the proposed unit from SEAC, Maharastra and
submitted Draft EIA Report based on Model TOR’s on June 28th 2014.The
proposed unit is located in Notified industrial Area, MIDC, Chincholi, As
the unit is within 5 KM from the proposed eco sensitive zone of the Nanaj
Sanctuary Great Indian Bustard sanctuary.
In the year 2014, Hon. Supreme Court had given directions to all State
Govts. to finalize the Eco Sensitive Zones(ESZ) for all the Protected Areas
coming under them. Further, directions were given by Hon. Supreme
Court that in absence of finalized ESZ or for a period till the ESZ gets
finalized, a distance of 10 Km from the boundary of PA would be treated
as ESZ.
Under such circumstances, as per the provisions in MoEF notification
dated 14.09.2006, any project in Cat. B coming in ESZ of a Protected
Area would be treated as Cat. A and hence the State Level EIA Authority
rejected the case and advised the company to approach MOEF in Delhi for
the clearance.
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, B-14/1
2
Hence this application is made for obtaining fresh TOR. As the unit is
located in IE, Chincholi which is notified industrial area established prior
to 2006 notification, Public hearing may be exempted for this unit.
2. Introduction of the Project
The proposed unit is to manufacture Bulk Drugs (APIs) to a tune of 1250
TPA. The salient features of the project are described in the table given
below
TABLE 1.0
Salient Features of the Project
Location B-14/1, MIDC, Chincholi (V), Mohol (Taluk), Solapur (D), Maharashtra.
Longitude and Latitude 17o44’39.8’’ N 75o 48’39.5’’ E
17o44’36.4’’ N 75o 48’47.4’’ E 17o44’32.4’’ N 75o 48’44.7’’ E
17o44’35.0’’ N 75o 48’37.7’’ E
Product Category 5(F) Bulk Drugs & Intermediates
Project Category as per EIA notification
Category A (located within 5 Km distance
from the proposed ESZ of GIB Nanaj
Sanctuary)
Proposed Activity Drugs & Drug intermediates- 1250 TPM
Total investment on the plant Rs. 95.0 Crores
Total Investment on Environmental
Infrastructure
Rs. 6.92 Crores
Total area of the plant 8.39 Acres
Total area of green belt 3.25 Acres
Water requirement Total water requirement for project will be 739 KLD. Fresh water will be 474 KLD and from water recycle 265 KLD
Source of water MIDC, Chincholi
Nearest habitation and distance
from the site
Kondi Village- 1.95 Km from the site (E)
Nearest surface water bodies Sina river is at a distance of 1.91 km
from the site
Nearest reserve forest There are no reserve forests in 10 km radius from the site
Environmentally sensitive areas within 10 km radius
None
Any national parks, wild life
sanctuaries within 10 km radius
GIB Nanaj Sanctuary is at a distance of
9.88 Kms from the site.
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, B-14/1
3
Proposed Eco Sensitive Zone of GIB
Nanaj Sanctuary- 0.6 Kms
Nearest air port and distance Solapur Airport-18.55 km
Nearest railway station and distance
Pakni Railway Station-3.95 km
National Highway NH-9 is at a distance of 0.52 Km from the site
i) Introduction of the company and proponent
The company has Headquarter in Hyderabad, India, and is catering to the
ever growing demand of Active Pharmaceutical Ingredients (API’s) from
single State-of-the-art manufacturing facility. Already established unit in
Chincholi MIDC (Maharashtra) and has built up a reputation for excellence
on the foundations of consistent high quality, a constantly expanding
product portfolio and timely launches of new API’s.
The in-house QC Laboratories are equipped with sophisticated
instruments to assure the quality of the raw materials, intermediates and
API’s. The company believes in quality by design and continuous
improvement in all aspects of its operations. By this endeavor, Sri Krishna
Pharma necessitates to recognize in the global market of Pharmaceuticals
as an important partner for API’s.
About Proponent
The management at Sri Krishna Pharmaceuticals Limited, consists of
highly qualified and richly experienced persons who have given the
company the edge in terms of quality, consistency, timely delivery and
ability.
The Group is headed by a technocrat with academic excellence. Dr. V.V.
Subba Reddy, Founder Chairman is a Post Graduate in Technology,
Doctorate in Science and a Post-Doctoral fellow from National Cancer
Institute, NIH, Maryland, USA. He also serves various trade associations,
Government bodies and Institutions as a representative of the
pharmaceutical industry in India.
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, B-14/1
4
About the Unit
Sri Krishna Pharmaceuticals Limited a largest producer of Paracetamol in
India with a capacity of 6000 MT/year and largest producer of Folic Acid in
the world with a capacity of 250 MT/year.
Quality Management: Strict quality control measures, Good
Manufacturing Practices (GMP) are integrated throughout the
manufacturing process to ensure strict adherence to the quality
parameters for both in-process and finished products.
3. Project Description
3.1 Production Capacity
Sri Krishna Pharmaceuticals Limited, B-14/1 intends to manufacture 1250
TPM of API products (Bulk Drug & Intermediates) products. Product wise
capacity is given below:
TABLE 2.0
PROPOSED PRODUCTS & CAPACITY
S.No Name of the
Products Quantity in
TPM Remarks
1A Paracetamol- 4 stages
50
Starting from PNCB - 4 Stages,
1B Paracetamol- 2 stages
950 Starting from penultimate stage -2
Stages
2 Ibuprofen 200
3 Domperidone 10
4 Docosa Hexaenoic
Acid (DHA) 20
5 Lovastatin 20
Total 1250
By Product
1 Acetic Acid
1192.0
Generated in the process and sold to consumers
2 Soap 80.0
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, B-14/1
5
3.2 Manufacturing Process
Typical Brief process description and process flow charts are given at
Annexure I
3.3 Raw Materials
List of raw material product wise is given at Annexure II
3.4 Water Requirement
The water requirement for process, domestic, gardening, boiler feed & for
cooling water make up is about 739 KLD. The source of water is already
available from existing water works of MIDC and the same is adequate
and satisfactory. The water balance for daily consumption is presented
below.
TABLE 3.0
Water Balance–Proposed
S.
No
Stream Water
requirement in KLD
Waste
Water discharge
in KLD
Proposed Method
of Treatment and Disposal
1 Process 290.0 352.0 Stripper, MEE and
ATFD (Condensate to RO)
2 Washings
5.0 5.0
3 Laboratory
washings
1.0 1.0
4 Scrubbers 25.0 25.0
5 Boiler 100.00*
10.0 ETP followed by RO ( RO Reject to MEE)
4 DM/Softener 3.0 3.0
5 Cooling &
Regeneration
255.00 26.0
6 Domestic 50.00 40.00 Sewage Treatment
Plant & reused for gardening &
flushing’s
7 Gardening 10.00 -
Total 739.0 462.0 *includes 85 KL condensate recycle
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, B-14/1
6
3.5 Wastes generation and control systems
3.5.1 Liquid Effluents
As detailed in Table 3.0 waste water generation would be 462.0 KLD. It is
proposed to segregate effluents into high COD and High TDS stream and
Low COD and Low TDS streams.
High TDS and High COD stream would be treated in stripper followed by
MEE and ATFD. The resultant sludge would be disposed to TSDF,
Hyderabad. The Low TDS stream would be treated along with MEE/ATFD
condensates in biological ETP followed by RO. The RO rejects would be fed
back to MEE. The Permeate from RO would be used for cooling tower
make up. Domestic effluents are treated in sewage treatment plant. Thus
the treatment system proposed is based on “Zero Liquid Discharge” (ZLD)
Concept
The schematic diagrams of ETP proposed are given in Figure 1.1 and
Figure 1.2 below
Pre
-Fe
asi
bil
ity
Re
po
rt
Sri
kri
shn
a P
ha
rma
ceu
tica
ls L
imit
ed
, B
-14
/1
7
Fig
1.1
Sch
em
ati
c T
reatm
en
t S
ch
em
e o
f H
igh
TD
S E
fflu
en
ts
E
fflu
en
t fr
om
Pro
cess
an
d
Aq
. D
isti
lla
te t
o
Ce
me
nt
Pla
nt/
TS
DF
Re
cov
ery
Wa
shin
gs,
Scr
ub
be
r
R
O R
eje
ct
To
TS
DF
Co
nd
en
sate
to
B
iolo
gic
al
T
rea
tme
nt
C
on
de
nsa
te t
o B
iolo
gic
al
Tre
atm
en
t
S
lud
ge
to
TS
DF
Eq
ua
liza
tio
n
Ta
nk
ME
E
AT
FD
Str
ipp
er
Ne
utr
ali
zati
on
Ta
nk
Se
ttli
ng
Ta
nk
Pre
-Fe
asi
bil
ity
Re
po
rt
Sri
kri
shn
a P
ha
rma
ceu
tica
ls L
imit
ed
, B
-14
/1
8
Fig
1.2
Lo
w T
DS
Eff
luen
t Treatm
en
t S
yste
m
Eff
lue
nts
fro
m u
tili
tie
s &
ME
E c
on
de
nsa
te
Slu
dg
e t
o T
SD
F
Pe
rme
ate
fo
r re
-use
R
eje
cts
to M
EE
Scr
ee
n
Ch
am
be
r
Slu
dg
e H
old
ing
Ta
nk
Ae
rati
on
Ta
nk
2
Eq
ua
liza
tio
n
Ta
nk
Ne
utr
ali
zati
on
Ta
nk
Cla
rifi
er
2 Ho
ldin
g
Ta
nk
Fil
ter
Pre
ss
Slu
dg
e C
ak
e
Ae
rati
on
Ta
nk
1
Cla
rifi
er
1
Sa
nd
filt
er
Ca
rbo
n
Fil
ter
Ult
ra
filt
rati
on
R
O
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, B-14/1
9
3.5.2 Solid wastes management
Hazardous and non - hazardous wastes generated from the proposed
project are detailed below. Mode of disposal are also identified and listed.
Adequate storage of hazardous waste is ensured at the site
TABLE 4.0
Solid Wastes and Disposal
S.No
Type of waste Schedule No.
Quantity in TPM
Disposal
Hazardous waste
1 ETP Sludge 34.3 30.0 CHWTSDF
2 MEE salts and inorganic residue
34.3 870.6
CHWTSDF
3 Spent carbon 28.2 308.4 CHWTSDF
4 Distillation bottom Residue/process sludge
20.3 775.6 Authorized cement Industries/ CHWTSDF
5 Spent solvents 28.5 40.0 CHWTSDF
6 Iron sludge 28.1 72.5 Authorized cement Industries
7 oil from process 5.1 20.0 Authorized recyclers/
CHWTSDF
8 Waste oil 5.1 0.2 Authorized recyclers/
CHWTSDF
9 E- Waste 31.1 As and when generated
Send to E- waste Recycler
10 Used Lead acid batteries
- As and when generated
Return to supplier for replacement in exchange
Biodegradable waste
1 ETP Bio sludge - 10.0
Composting and used as manure for
gardening
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, B-14/1
10
Non Biodegradable waste
1 Waste paper - 100.0
Kgs/month Sale
2 Corrugated boxes - 500.0
Kgs/month Sale
3 Broken glass - 100.0
Kgs/month Sale
4 Decontaminated
used drums -
500.0
Kgs/month Sale
5 Decontaminated HDPE Bags
- 500.0
Kgs/month Sale
6 Coal ash - 280.0 Sale
CHWTSDF facility at Ranjangaon which is at a distance of 200 Km from
the site has agreed to cater the solid waste from the proposed site.
Transport of Hazardous wastes to TSDF is done by the CHWTSDF. In case
other hazardous wastes, authorized recyclers will transport the wastes.
4. Site Analysis
4.1 Plant Location
M/S Sri Krishna Pharmaceuticals Limited, B-14/1, MIDC, Chincholi(V),
Mohol (T), Solapur(D), Maharastra state. The site is situated at the
following Latitudes and longitudes
17o44’39.8’’ N 75o 48’39.5’’ E
17o44’36.4’’ N 75o 48’47.4’’ E 17o44’32.4’’ N 75o 48’44.7’’ E 17o44’35.0’’ N 75o 48’37.7’’ E
The land area of the plant is 8.39 acres. The nearest habitation from the
site is Kondi (V) at a distance of 1.95 km. The nearest railway station
located at Pakni 3.95 KM from the Plant. Great Indian Bustard (GIB)
Nanaj Sanctuary which is ecologically sensitive area is at a distance of
9.88 Km from the site and the proposed Eco sensitive zone of the GIB
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, B-14/1
11
sanctuary is at a distance of 0.6 Km from the site. There are no reserve
forests in 10 Km radius.
Following are the surroundings of the site
North – Road followed by LHP Limited
East- Betul Oil company
South- Sri Krishna Pharmaceuticals unit -V
Topo graphic features of the site and 10 KM study area and base map are
given at Fig 1.3 & 1.4.
Plant & Green Belt Photographs are given at Fig. 1.5
Site lay out map is given at Fig 1.6
Pre
-Fe
asi
bil
ity
Re
po
rt
Sri
kri
shn
a P
ha
rma
ceu
tica
ls L
imit
ed
, B
-14
/1
12
Fig
1.3
To
po
Sh
eet
of
the 1
0 K
M s
tud
y a
rea
Pre
-Fe
asi
bil
ity
Re
po
rt
Sri
kri
shn
a P
ha
rma
ceu
tica
ls L
imit
ed
, B
-14
/1
13
Fig
1.4
Base m
ap
of
the s
tud
y a
rea
Pre
-Fe
asi
bil
ity
Re
po
rt
Sri
kri
shn
a P
ha
rma
ceu
tica
ls L
imit
ed
, B
-14
/1
14
Fig
1.5
Pla
nt
Ph
oto
grap
hs
Pre
-Fe
asi
bil
ity
Re
po
rt
Sri
kri
shn
a P
ha
rma
ceu
tica
ls L
imit
ed
, B
-14
/1
15
Fig
1.6
Sit
e L
ay O
ut
Pla
n
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, B-14/1
16
5.0 Planning in Brief
The project is envisaged to be completed by November 2017, and the
production shall be initiated thereon. Consultants are identified for
preparing the detailed project report.
6. Resource requirements 6.1 Power Requirement and Supply/Source
The total power requirement for the proposed project is 4000 HP. It shall
be sourced from MSEDCL and D.G sets are proposed as alternative to
Power failure.
6.2 Production facilities, Utilities and effluent handling facilities
It is proposed to add additional production facilities, utilities and effluents
treatment infrastructure with an investment of Rs.95.0 Crores. The details
are outlined in the below table
TABLE 5.0
S.NO Details
Capacity/
No Proposed
Production facilities
1 Production Blocks Nos 6
2 Bio Tech Blocks Nos 2
3 Clean rooms Nos 1
4 Boiler (coal Fired) TPH 1 x20 & 1x10*
5 DG sets KVA 2 X 1000
6 Cooling tower TR 2500
7 Softner/DM plant M3/hour 2.5
8 Fresh water RO Plant M3/hour 2.0
Effluent handling & treatment facilities
9 Collection tanks-Storage
KL 500
10 Neutralisation tanks KL 10
11 Stripper, MEE, ATFD KLD 2 X 200
12 RO & Biological treatment
KLD 400
13 Sewage treatment plant KL 40
* 1 X 10 TPH Boiler is Stand by boiler
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, B-14/1
17
6.3 Land Requirement
The unit currently has 8.39 acres of land and out of which 3.25 acres of
green belt will be developed. The land requirement for proposed activities
will be 10052 Square meters (2.5 Acres) which can be met from existing
open area. Below table provides the land statement. Detailed site lay out
plan outlining proposed activities is given at Figure 1.6
Table 6.0 Land Statement
S. No Block Area in Sq. meters
1 Raw Material Stores-1 813.75
2 Raw Material Stores -2 813.75
3 Utility Block 273.0
4 Boiler House 273.0
5 Coal & Ash yard 126.0
6 Engineering work shop 126.0
7 ETP 199.5
8 Hazardous waste storage area 199.5
9 MEE 399.0
10 Production Block-I Para 494.0
11 Production Block-II Para 503.75
12 Production Block-I Dom 494.0
13 Production Block- II Dom 503.75
14 Production Block-I Ibu 503.75
15 Production Block-II Ibu 494.0
16 Biotech Block-I 503.75
17 Bio Tech Block- II 503.75
18 Above ground acid storage tank 494.0
19 Finished goods storage 494.0
20 Admn Office, QA, QC 503.75
21 U/G Storage tanks 1026.0
22 Transformer yard 120.0
23 Electrical room 40.0
24 Generator room 40.0
25 Water sump, Pump house 90.0
26 Security 20.0
Total 10052.0
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, B-14/1
18
7.0 Air Pollution
The Sources of air emissions from the plant are from 20 TPH coal fired
Boiler and stand by 10.0 TPH coal fired boiler and DG sets
The process emissions Contain Acetic acid fumes, CO2, H2 & HCl. Acetic
acid fumes and HCl are scrubbed with caustic and scrubbed waste send to
MEE. Below Table gives proposed emission sources from the plant
Table 7.0 Emission Source –Proposed
S.No
Parameter Capacity Fuel Anticipated emissions
Control system
1 Process --- -- HCl, Acetic acid fumes
Scrubber
2 Boiler Stack 20 TPH; 10
TPH stand by
Coal SPM, SO2,
NOx
Common stack
with height of 50 meters,
cyclone and dust collector
3 DG sets 2x1000 KVA Diesel SPM,SO2
&NOx
Stack Height 6.5 Mts,
Acoustic enclosures
8.0 Bulk Chemical Storages:
Following bulk chemical storage facilities are proposed
Table No 8.0
Storage facilities of bulk chemicals
S.No Name of the
raw material.
MOC Mode of
storage
No Of
Tanks
Storage
Quantity
1 Isopropyl alcohol
MS Below Ground
1 20KL
2 Isobutyl
Benzene
MS Below
Ground
1 20KL
3 Isobutyl
Acetophenone
MS Below
Ground
1 20KL
4 Isopropyl Chloro
MS Below Ground
1 20KL
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, B-14/1
19
acetate
5 Acetone MS Below Ground
1 20KL
6 O-Xylene MS Below
Ground
1 20KL
7 Toluene MS Below
Ground
2 40KL
8 Methanol MS Below Ground
1 20KL
9 MIBK MS Below Ground
1 20KL
10 Caustic Lye (48%)
MS Above Ground
1 25KL
11 Sulphuric Acid MS Above
Ground
2 50KL
12 Acetic
anhydride
Aluminu
m
Above
Ground
1 25KL
13 HCl PP-FRP Above Ground
2 50KL
14 Liquor ammonia
25%
MS Above Ground
1 25KL
15 Acetic acid SS Above Ground
2 50KL
16 Ammonia-LIQ cylinders Above Ground
1 25KL
9. Baseline data studies
We have a unit at B-14/2 in MIDC Chincholi which is in the same MIDC
of the proposed site for which baseline data has been collected during the
period of April 2016 to June 2016 so we request you to kindly allow us to
consider the same data for current study.
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, B-14/1
20
10. Project Financial
The estimated cost of the proposed project is approximately 95.0 Crores.
Out of this Rs. 6.92 Crores will be for effluents treatment facilities and
rest for other process equipment and safety equipment
Project cost
Rs. In
Crores
Plant& machinery 50.0
Civil & Structural 15.0
Total 65.0
Pipe lines & insulation
20% on plant &
machinery 10.0
Electricals & instrumentation 10% on plant & machinery 5.0
Erection & commissioning & painting
8% on plant &
machinery and structures 4.0
Safety & Environment 10.0
Furniture, fixtures, computers, lighting etc 0.5
Total 94.5
Contingencies & pre-operative
expenses 0.5
Project cost say 95.0 Crores
Annexure I
Typical technical details of the proposed products
PARACETAMOL
Process description and flow sheets
Brief manufacturing process of Paracetamol
Stage-1 (Hydrolysis)
Para Nitro Chloro Benzene is treated with aqueous sodium hydoexide at a temperature of 135-
140oC in an autoclave and neutralized with sulphuric acid to get Para Nito Phenol.
Stage- 2 (Reduction)
Para Nitro Phenol is reduced in boiling water under mild acidic condition with iron poweder
and acetic acid to get Para Amino Phenol,
Stage -3 (Acetylation)
Para Amino Phenol is condensed with Acetic Anhydride in aqueous medium to get
paracetamol and acetic acid.
Stage-4 (Purification)
Paracetamol technical is dissolved in hot water, treated with carbon, crystallized to get
Paracetamol with is dred, milled and packed in LDPE lined HDPE bags.
CHEMICAL PATHWAY OF PARACETAMOL SYSNTHESIS
Stage I -P-Nitro Phenol:
Cl
+ 2NaOH + NaCl + H2O
ONa
NO2
161
NO2
PNCB
157.5
Step 2.
ONa
NO2
161
+ 0.5 H2SO4
OH
NO2
+ 0.5 Na2SO4
0.5 x 142
139
Step 1.
2 x 40 58.5 18
Para Nitro Phenol
(PNP)
OH
NO2
+ 18 Fe + 7H2O+ 9FeO + 3Fe3O4+ xCH3COONa + xH2O
82
7 x 139
18x55.84 7x18xCH3COOH + xNaOH
OH
NH2
7 x 109
60 40 6Fe3O3.5(Av)
6 x 223.52
7
Stage -II - P-Amino phenol:
PNP Para Amino Phenol
(PAP)
18
O
O
S T A G E I II - P a ra c e ta m o l T e c h n ic a l
O H
N H 2
+C H 3 C
O
CC H 3
O H
N H C O C H 3
+ C H 3C O O H
6 0
1 5 11 0 21 0 9
P A P A c e tic A n h yd r id e P a ra c e ta m o l
S ta g e - IV - P a ra c e ta m o l P h a rm a
O H
N H C O C H 3
O H
N H C O C H 3
+ S pen t ca rbonA ctiv e C a rbon
Ph a rm a M L
PARACETAMOL
PROCESS FLOW DIAGRAM
4-Nitrochlorobenzene
Caustic soda Lye
Water
Stage I
Sulphuric acid
Aq layer
PNP
PAP ML / Water
Dilute Acetic acid
Iron powder
Caustic soda Lye
Stage II
Iron sludge
Hydros
SMBS Aq layer
PAP PAP ML
Pharma ML
Acetic anhydride
Soda ash
EDTA
Hydros
SMBS
Stage III
Hydrolysis
Conversion of PNCB to Nitrophenol
(PNP)
Neutralisation
Reduction
Conversion of PNP to
Aminophenol (PAP)
Filtration
candle filter
Cooling and Filtration
Pusher Centrifuge
Acetylation
Conversion of 4-Aminophenol
(PAP) to Paracetamol technical
Filtration
Pusher Centrifuge
Process water/Pharma ML
Soda ash
Activated carbon
Hydros
SMBS
Stage IV
Hydros Pharma ML
DM Water
Acetaminophen (Paracetamol) pharma (wet)
Carbon treatment
Filtration through Leaf
filter and Polishing filter
Recrystallisation
(cooling)
Filtration through
Agitated Nutsche Filter
Acetaminophen Technical
Annexure II
List of Raw Materials
List of Raw Materials of Paracetamol (Starting
from PNCB)
S.No Name of raw material
Qty
(Kgs/day)
1 PNCB 2008.7
2 Caustic Lye (48%) 8486.6
3 Sulphuric Acid 750.2
4 Iron Powder 1810.4
5 Acetic Acid (20%) 841.8
6 Acetic anhydride 1273.6
7 EDTA 1.7
8 Hydros 3.3
9 SMBS 1.7
10 Activated Corbon 15.0
11 Sodium Hydro Sulphite(Hydros)
1.7
12 Sodium Meta Bisulphite(SMBS) 1.7
13 Caustic flakes 11.7
List of Raw Materials of Paracetamol
(Starting from PAP)
S.No Name of raw material
Qty
(Kgs/day)
1 PAP (1% ) moisture) 25237.8
2 Acetic anhydride 24192.8
3 EDTA 31.7
4 Hydros 63.3
5 SMBS 31.7
6 Activated Corbon 285.0
7
Sodium Hydro
Sulphite(Hydros) 31.7
8
Sodium Meta
Bisulphite(SMBS) 31.7
9 Caustic flakes 221.7
List of Raw Materials of Ibuprofen
S.No Name of raw material
Qty
(Kgs/day)
1 Mono Chloro acetic acid 4572.9
2 Iso propyl alcohol 3352.8
3 Sulphuric acid 1668.0
4 Sodium bi carbonate 328.9
5 Sodium carbonate 82.2
6 Isobutyl benzene 5154.0
7 Acetyl chloride 3412.2
8 Aluminum chloride 5856.8
9 Conc. Hcl 30% 509.3
10 Liq Ammonia 25 % 509.3
11 Sodium metal 1265.6
12 Isopropyl alcohol 16718.0
13 CS Lye 48% 5872.6
14 Sodium dichromate dehydrate 3518.7
15 Sulphuric acid 6481.8
16 Acetone 16297.1
17 N- Hexane 9074.5
List of Raw Materials of Domperidone S.No Name of raw material Qty (Kgs/day)
1 Orthophenylene di amine(OPDA) 186.0
2 Methyl Aceto acetate(MAA) 199.7
3 Xylene 797.3
4 Caustic lye 48 % 165.0
5 Carbon 12.3
6 Conc. HCl 30 % 245.7
7 1- bromo-3-chloro-propane 223.3
8 Toluene 796.7
9 Potassium carbonate 210.0
10 Conc. HCl 30 % 213.3
11 Caustic lye 48 % 13.3
12 N- Methyl Piperidone 240.0
13 Ethyl chloro formate 320.0
14 CS Flakes 193.3
15 Toluene 863.3
16 Methanol 336.7
17 Raney Nickel 6.7
18 Ammonia gas 50.0
19 Hydrogen 3.3
20 DCNB 343.3
21 K2 CO3 200.0
22 Toluene 573.3
23 Potassium carbonate 100.0
24 Potssium chloride 106.7
25 Toluene 956.7
26 Methanol 573.3
27 Raney Nickel 23.3
28 Hydrogen 10.0
29 Urea 170.0
30 Caustic lye 47 % 546.7
31 Ammonium chloride 383.3
32 Carbon 3.3
33 Conc. HCl 30 % 140.0
34 Ammonia 30% 286.7
35 Soda ash 123.3
36 MIBK 1190.0
37 Methanol 3176.6
38 Carbon 13.3
39 Acetic acid 116.7
40 Ammonia 33.3
List of Raw Materials of Omega-3
S.No Name of raw material
Qty
(Kgs/day)
1 Sea water 32016.0
2 Dextrose 17342.0
3 Toluene 6670.0
4 Crude oil 2668.0
5 Alkali Solution 1334.0
List of Raw Materials of Lovastatin
S.No Name of raw material
Qty
(Kgs/day)
1 Mixed material 5467.4
2 Dextrose 19400.4
3 Seed 1657.8
4 Toluene 49911.9
5 Iso propyl alcohol 1410.9
6 Activated carbon 9347.5
Recommended